Citius Oncology Inc. Common Stock (CTOR)
Stock · NASDAQ · Health Care
$0.776as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta100.0%
Support level
$0.666612
Industry
Biotechnology: Pharmaceutical Preparations
About CTOR
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Bio…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- citiusonc.com/
Fundamentals
- 1-day range
- $0.7538$0.7968
- Market cap
- $58.15M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.47
- Dividend yield
- —
- Beta
- 3.50
- Avg. volume
- 83.0K
52-week range
$0.491$2.25
Forecasts
1 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$4
+415.5%
Median
$4
+415.5%
Low
$4
+415.5%
Citius Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CTORCitius Oncology Inc. Common Stock$0.776▼ 1.77%Market cap $58.15MP/E —$0.491$2.25
- DOMHDominari Holdings Inc. Common Stock$2.39▼ 4.02%Market cap $58.34MP/E —$2.19$8.4
- BOLDBoundless Bio Inc. Common Stock$2.83▼ 1.05%Market cap $57.73MP/E —$0.9612$3.16
- DWTXDogwood Therapeutics Inc. Common Stock$2.6▲ 12.07%Market cap $57.51MP/E 1.84$1.28$9.5
- XLOXilio Therapeutics Inc. Common Stock$9▼ 0.22%Market cap $59.51MP/E —$6.47$12.74
- ANVSAnnovis Bio Inc. Common Stock$1.72▼ 4.97%Market cap $59.59MP/E —$1.54$5.5
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.22▼ 1.61%Market cap $59.73MP/E —$1.02$1.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTOR Citius Oncology Inc. Common Stock | $58.15M | — | $0.776 | ▼ 1.77% | $0.491$2.25 |
| DOMH Dominari Holdings Inc. Common Stock | $58.34M | — | $2.39 | ▼ 4.02% | $2.19$8.4 |
| BOLD Boundless Bio Inc. Common Stock | $57.73M | — | $2.83 | ▼ 1.05% | $0.9612$3.16 |
| DWTX Dogwood Therapeutics Inc. Common Stock | $57.51M | 1.84 | $2.6 | ▲ 12.07% | $1.28$9.5 |
| XLO Xilio Therapeutics Inc. Common Stock | $59.51M | — | $9 | ▼ 0.22% | $6.47$12.74 |
| ANVS Annovis Bio Inc. Common Stock | $59.59M | — | $1.72 | ▼ 4.97% | $1.54$5.5 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $59.73M | — | $1.22 | ▼ 1.61% | $1.02$1.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 8/17/2026
- Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving PremarketBenzinga · 8/17/2026
- Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M EstimateBenzinga · 8/14/2026
- Citius Oncology Expands Board with Appointment of Independent Director Jonathan PeriYahoo · 8/12/2026
- Citius Oncology Reports Strong Commercial Momentum for its Cancer TreatmentYahoo · 8/5/2026
- Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400MBenzinga · 8/5/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 14.13M
- Total value held
- $8.75M
- Institutional holders
- 13
Top holders this quarter
- Unknown9.19M
- Unknown3.84M
- Unknown534.8K
- Unknown264.7K
- Unknown107.4K
- Unknown47.5K
- Unknown45.7K
- Unknown42.9K
- Unknown36.8K
- Unknown11.7K
See the full, filterable feed with live charts on the MarketWall dashboard.